Navigation Links
Impact Equalizer 8-Channel Electronic Pipettor, 5-250L

ProductsImpact Equalizer 8-Channel Electronic Pipettor, 5-250L
Company Matrix Technologies Corporation
Item Impact Equalizer 8-Channel Electronic Pipettor, 5-250L
Features 
Description Equally Spaced, Expandable, Multichannel Pipettor

The Equalizer replaces fixed multichannel pipettors and instantly boosts productivity with an industry breakthroughequal tip spacings that expand with the simple adjustment of a slide rod. This innovation allows the quick and easy transfer of liquids between vessels with different configurations.

Adjustable and Equal Tip-To-Tip Spacing
The Equalizers tips can be spaced anywhere from 9mm (microplates) to 14.15mm (12 or 13mm tubes and 48 well plates) in increments of 0.1mm. The distance between tips is always equalsimply set the desired spacing on the scale and pull or push the rod.

No Handling, No Contamination
The unique push/pull rod allows you to spread the tips to your desired spacing without touching the tip fittings. This lessens the possibility of contaminating the tip fittings or samples.

Two Levels of Software
The Equalizer is available with Impact or Impact2 software (see Impact/Impact2) so it can operate at up to five speed settings and is capable of storing up to six 40-step programs.

Simple Calibration
In-lab calibration can be performed quickly and easily. The software provides a trail of calibration information for your lab records.

Long-Lasting, Rechargeable Batteries
Every Equalizer comes with a power supply adapter and a set of NiCad batteries strong enough to deliver a full day of pipetting. The batteries are easy to access so replacement can be done in seconds without any special tools.

Info Matrix Technologies Corporation
Customer Service: (866) 229-9770
Web site: http://www.matrixtechcorp.com/index.aspx

Related medicine products :

1. Tangent Posterior Impacted Instrument Set
2. TANGENT Posterior Impacted Instrument Set
3. Palm Style Impactor Bone Awl
4. Soft Impact Mallet
5. The Impact Walker
6. Micro Impactor
7. Impact Single Channel Pipettor, 5-250L
8. Impact2 Single Channel Pipettor, 5-250L
9. Impact Shorty, 5-250L
10. Impact2 Shorty, 5-250L
11. Impact2 16-Channel Electronic Pipettor, 1.0-30L
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...chest scans that screen smokers for lung cancer ca...ms are used to scan women for breast cancer,// acc... people in whom lung tumors were detected early by...0-year survival rate of 92% which is comparatively...
...sity epidemic is also causing increased fuel consu...ealth.// Statistics have shown that Americans are...to their vehicles than they used to in 1960 becaus...oughly two dozen pounds heavier which amounted to ...
...commissioned a programme to screen six-month-old i...will focus on monitoring babies delivered from HIV...with success in 11 clinics and one hospital. It i... population in Botswana, the infection rate as dep...
...a study published on Tuesday, the younger brains o...cts on social behavior.// However, the researcher...ake teens indulge in heavy drinking that could res...e under-developed regions of the brain. They used...
Other Medicine News:Health News:Scans Aid in Early Lung Cancer Detection 2Health News:Brain development in teens curbed by alcohol tolerance 2
(Date:9/3/2008)...URG, Md., Sept. 3 /- Panacea Pharmace... Patent Number 7,413,737 covering,antibodies again...HAAH), a,proprietary human cancer biomarker and th...in collaboration with the Massachusetts Institute ...ldwide rights to this patent,for development of hu...
(Date:9/3/2008)...o be Evaluated in Repeat-Dosing Study in Subjects ...irstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq: S... clinical trial (SB-509-801) to evaluate its drug,...nerative motor-neuron disease for which there,are ... drug, SB-509, is an injectable formulation of a p...
(Date:9/2/2008)... September is Prostate Cancer Awareness Month, ...- September is,Prostate Cancer Awareness Month, an...nnounce a revolutionary new way to treat prostate ...of radiation. Prostate cancer is,the most common f...erKnife CEO, James G. Schwade, M.D., says, "for ma...
(Date:9/2/2008)...Call Scheduled for Today - Tuesday, September 2, 2... Time, MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire...q: ALXA ) today announced positive results from,i...o(R) loxapine) in,schizophrenic patients with acut...04 met the primary endpoint of the trial, which wa...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 3Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 4Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 5Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 6Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 7Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 8Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 9Chiropractic Can Offer Relief from Stress Related Pain Health Problems 21650 1Chiropractic Can Offer Relief from Stress Related Pain Health Problems 21650 2Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 1Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 2Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 3Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 4Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 5Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 6Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 7Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 8Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 9Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 10REM sleep associated with overweight in children and adolescents 21643 1REM sleep associated with overweight in children and adolescents 21643 2REM sleep associated with overweight in children and adolescents 21643 3Cell Therapeutics Inc Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 5947 1Cell Therapeutics Inc Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 5947 2